TipRanks
Go Ultimate55% OFF

John P. Hamill Insider Profile

11 Followers

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, holds 43.53K shares in Aprea Therapeutics (Ticker: APRE), holds 72.80K shares in Windtree Therapeutics (Ticker: WINT), holds 82.23K shares in Trevena (Ticker: TRVN).

John P. Hamill's Trading History

APRE
Aprea Therapeutics
Mar 16, 2026SrVP/CFO/Prin Fin & Acct OfcrUninformative Buy―$21.07K
WINT
Windtree Therapeutics
Jul 26, 2022SVP & CFOInformative Buy1.08K$873.60
TRVN
Trevena
Jun 04, 2019VP Fin,Princ Fin&Acct OfficerInformative Buy8.70K$904.57
CLRB
Cellectar Biosciences
―Interim CFO――

You May Also Like

John P. Hamill insider profile FAQ

What is the percentage of profitable transactions made by John P. Hamill?
The percentage of profitable transactions made by John P. Hamill is 10%.
What is the average return per transaction made by John P. Hamill?
The average return per transaction made by John P. Hamill is -48.80%.
What stocks does John P. Hamill hold?
John P. Hamill holds: APRE, TRVN, CLRB, WINT stocks.
What was John P. Hamill's most profitable transaction?
John P. Hamill’s most profitable transaction was an Informative Buy of TRVN stock on June 4, 2019. The return on the trade was 19.80%.
What is John P. Hamill's role in Aprea Therapeutics?
John P. Hamill's role in Aprea Therapeutics is SrVP/CFO/Prin Fin & Acct Ofcr.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.